Successful meeting of the consortium partners to follow-up on the project and discuss next strategies

Successful meeting of the consortium partners to follow-up on the project and discuss next strategies
June 30, 2022

After seven months of intense telematic work on the RBDCOV project , the partners were able to meet in person in Amer, Girona, at HIPRA facilities to further discuss the strategies to achieve the objective of a Covid-19 vaccine for children, adolescents and immunocompromised people using a recombinant protein.

Asphalion is proud regulatory partner of RBDCOV by carrying out the regulatory pathway throughout the project: seeking scientific advice for the RBDCOV clinical trials with the European regulatory authorities; preparing the required documents to support clinical trial applications and supporting the preparation of the eCTD registration dossier currently under rolling review, among other regulatory activities.  We work together with an international consortium that includes companies and institutions from five European countries.

Our participation in several EU-funded, cutting-edge projects allows us to be at the forefront of innovation and are an added value to our know-how, heightening our position in the COVID-19 vaccine development. It is both an honour as well as a great challenge to us to be part of this project!!

Check the project website to be up-to-date:


You can also contact us for further information: info@asphalion.com

Search News & Events

  • Filter by category


Related news and events

In2Sight | 4th annual meeting 3RS congress

At ASPHALION, we are part of the IN2SIGHT consortium, an EU-funded project, and we are delighted to be currently participating in the 4th annual meeting

Course | Regulatory aspects of vaccine development

TRANSVAC2 supported innovation for both prophylactic and therapeutic vaccine development by providing high-quality technical services across four different service platforms: Technology (for process development and GMP production), Immunocorrelates & Systems Biology, Animal models, and support for Clinical Trials. TRANSVAC also offered training courses to provide fundamental and advanced knowledge on a wide-range of vaccine development-related topics.


A lot of things have happened during these past three months. We received an award from AEFI as most engaged Company with its employees’ traning;

For further information

If you are interested in our services, or wish to get in touch for a general enquiry, please contact us for more information.

Fill the form and we will contact you as soon as possible.

You can also follow us on:

Schedule a Free Meeting

Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts. 

We will be happy to assist you!

Schedule a meeting